Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency; - Acid sphingomyelinase deficiency (ASMD) is a rare, progressive and potentially life-threateni

Media coverage

• Title	Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency
  Media name/outlet	Biotechgate
  Country/Territory	Switzerland
  Date	31/01/20
  URL	www.biotechgate.com/gate/v3/news_details.php?news_id=192393&page_id=?next=1
  Persons	Melissa Wasserstein

• Title	Sanofi announces positive results from phase 2/3 trials of olipudase alfa to treat acid sphingomyelinase deficiency
  Media name/outlet	PharmaBiz
  Country/Territory	India
  Date	31/01/20
  URL	www.pharmabiz.com/NewsDetails.aspx?aid=120851&sid=2
  Persons	Melissa Wasserstein

• Title	Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency; - Acid sphingomyelinase deficiency (ASMD) is a rare, progressive and potentially life-threateni
  Media name/outlet	PR Newswire
  Country/Territory	United States
  Date	30/01/20
  Persons	Melissa Wasserstein

• Title	Sanofi : Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency
  Media name/outlet	Thomson Reuters One
  Country/Territory	United States
  Date	30/01/20
  Persons	Melissa Wasserstein